4-(4-aminophenoxy)butyric acid | 851757-04-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(4-aminophenoxy)butyric acid
• 英文别名: 4-(4-amino-phenoxy)-butyric acid；γ-(4-Amino-phenoxy)-buttersaeure；4-(4-Amino-phenoxy)-buttersaeure；4-(4-Aminophenoxy)butanoic acid
• CAS: 851757-04-5
• 化学式: C₁₀H₁₃NO₃
• mdl: MFCD09259374
• 分子量: 195.218
• InChiKey: ZJXDBOFLMIGAAM-UHFFFAOYSA-N

物化性质

• 熔点：
  145.5-146.0 °C
• 沸点：
  429.8±25.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-aminophenoxy)butyric acid 、 6-(2,6-二氯苯基)-8-甲基-2-甲基磺酰基-8H-吡啶并[2,3-d]嘧啶-7-酮 生成 4-{4-[6-(2,6-Dichloro-phenyl)-8-methyl-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino]-phenoxy}-butyric acid
  参考文献：
  名称：

  Structure–activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1

  摘要：

  A series of 2-anilino-6-phenylpyrido[2,3-d]-alpyrimidin-7(8H)-ones were synthesized and evaluated for their inhibitory properties against the non-receptor kinase c-Src and the G2/M checkpoint kinase Weel. Overall, the compounds were 10-100-fold more potent inhibitors of c-Src than Weel, and variation of substituents on the 6-phenyl ring did not markedly alter this preference. Solubilizing substituents off the 2-anilino ring in many cases increased Wee I activity, thus lowering this preference to about 10-fold. 5-Alkyl substituted analogs were generally Weel selective, but at the expense of absolute potency. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.079
• 作为产物：
  描述：

  4-(4-nitrophenoxy)butanoic acid 在 palladium 10% on activated carbon 、 甲酸铵 作用下， 以 甲醇 为溶剂， 以95%的产率得到4-(4-aminophenoxy)butyric acid
  参考文献：
  名称：

  [EN] POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO
  [FR] POLYCONJUGUÉS POUR L'ADMINISTRATION DE DÉCLENCHEURS D'ARNI À DES CELLULES TUMORALES IN VIVO

  摘要：

  本发明涉及将RNA干扰（RNAi）触发物传递至体内整合素阳性肿瘤细胞的组合物。这些组合物包括以RGD配体为靶向的两性膜活性多胺，可逆地修饰为酶可切割二肽-酰胺基苄-碳酸酯掩蔽剂。修饰掩盖了聚合物的膜活性，而可逆性提供了生理响应性。这些可逆修饰的多胺（动态多共轭物或共轭物）进一步与RNAi触发物共价连接。

  公开号：

  WO2015021092A1

文献信息

• AMINO ACID AMIDES OF PHENOXYBUTYRIC ACID DERIVATIVES
  申请人：LALEZARI IRAJ

  公开号：US20120232120A1

  公开（公告）日：2012-09-13

  A compound of the formula: where X is phenyl substituted at the 3, 4 and 5 positions with R1, R2 or R3 which are selected from hydrogen, chloro, lower alkyl of 1 to 5 carbons, phenoxy, phenyl, naphthyl, or phenyl (lower) alkyl where the lower alkyl group has 1-5 carbon atoms and m is 0 or 1; Y is —CONH— or —NHCONH— where the nitrogen atoms are unsubstituted or substituted with other phenoxyisobutyric acid derivatives, or the residue of a phenoxyisobutyric acid and n is 0 or 1; Z is unsubstituted phenyl when m is 1 and n is 1; when Y is 0, X is 0; Z is also substituted.

  式的化合物： 其中X是苯基，取代在3、4和5位与R1、R2或R3，它们从氢、氯、1至5个碳原子的低烷基、苯氧基、苯基、萘基或苯基（低）烷基中选择，其中低烷基基团有1-5个碳原子，m为0或1；Y为—CONH—或—NHCONH—，其中氮原子未取代或取代为其他苯氧异丁酸衍生物，或苯氧异丁酸的残基，n为0或1；当m为1且n为1时，Z为未取代的苯基；当Y为0时，X为0；Z也被取代。
• Convergent Versus Divergent Three-Step Synthesis of the First (4-Aminophenoxy)alkanoic Acid–Based Tripodal Melamines
  作者：Cristina Morar、Lavinia Cost、Pedro Lameiras、Cyril Antheaume、Mircea Darabantu

  DOI：10.1080/00397911.2015.1041048

  日期：2015.7.18

  (divergent approach), two synthetic routes toward novel tripodal N-substituted melamines as s-triazine derivatives of (4-aminophenoxy)acetic acid or of 4-(4-aminophenoxy)butyric acid are comparatively defined. The key steps consist of Williamson etherification of N-masked forms of 4-aminophenol and acidic hydrolysis of the N- and/or O-protected (4-aminophenoxy)alkanoic segments. GRAPHICAL ABSTRACT

  摘要 从 N-（4-羟基苯基）乙酰胺（扑热息痛，收敛法）或氰尿酰氯与 4-氨基苯酚反应（发散法）开始，两条合成路线向新型三足 N-取代三聚氰胺作为（4 -氨基苯氧基)乙酸或4-(4-氨基苯氧基)丁酸是比较定义的。关键步骤包括 4-氨基苯酚的 N-掩蔽形式的威廉姆森醚化和 N-和/或 O-保护的（4-氨基苯氧基）链烷烃链段的酸性水解。图形概要
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo
  申请人：Arrowhead Madison Inc.

  公开号：US20150045573A1

  公开（公告）日：2015-02-12

  The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand-targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.

  本发明涉及用于在体内向整合素阳性肿瘤细胞传递RNA干扰(RNAi)触发剂的组合物。这些组合物包括以RGD配体为靶向的两性膜活性聚胺，其可逆修饰为酶可切割的二肽-酰胺基苯甲酸酯掩蔽剂。修饰掩蔽了聚合物的膜活性，而可逆性提供了生理响应性。可逆修饰的聚胺（动态聚结合物或结合物）进一步共价连接到RNAi触发剂。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。